| Contact Details |
| Office Address: | Cipla Limited - Mumbai
Mumbai Central
Mumbai, MH, 400008
Phone : +91-22-23082891/23095521
Fax : +91-22-23070013/23070393
|
| Be the first person to write a business review for Cipla Limited - Mumbai. |
|
| Related Companies |
 | Citadel
Citadel, the denotive meaning of which is "a fortress on a high ground i.e. protecting and dominating" took its birth in Chennai three decades ago. The untiring and dedicated efforts of its founder members and the personnel employed made the Company blossom and find for itself a niche in the minds of the Medical Profession.
Visit Website |
|  | Citadel Fine Pharmaceuticals Limited - Chennai.
Manufactures a wide range of products in response to therapeutic and marketing dynamics that comprise antibiotics, anti-inflammatory drugs, anti-diarrhoeals, analgesics, anti-cold preparations, antacids, haematinics and tonics.
Visit Website |
| | Clarion Drugs
Manufacturers of Pharmaceutical Intermediates & Bulk Drugs, in India. Company is a multi process plant. It performs a very wide range of reactions. Equipped with a state of art machinery & utilities, it is a multi purpose plant. The Company offers major intermediates & bulk drugs for the International Pharmaceutical Industry.
Visit Website |
|  | Cooper Pharma
Established in the year 1959 to develop and manufacture quality pharmaceutical formulations, Cooper Pharma is backed by its efficient directors, who are pharmacy graduates. With this knowledge base and the firm's dedicated efforts, the product range has been expanded and the quality has been improved upon.
Visit Website |
|  | Cosmos
Cosmos Plastics & Chemicals was established in 1996. Company is buyer, traders & stockists of all chemical, solvent, plastic raw materials, waxes, oils etc. A strong emphasis on quality that is our company logo ?CPC' is the preferred name of customers in all over India. The best service is our motto.
Visit Website |
|
| News |
Cipla shareholders approve proposal to raise up to Rs 3,000 crore
Posted on 17th August 2019 |
.jpg) |
Drug major Cipla on Saturday said its shareholders have approved a proposal to raise up to Rs 3,000 crore through issuance of equity shares or other securities convertible into equity shares. Drug major Cipla on Saturday said its shareholders have approved a proposal to raise up to Rs 3,000 crore through issuance of equity shares or other securities convertible into equity shares. Read More |
|
|
|
|
Cipla clocks ₹447 crore profit in Q1
Posted on 7th August 2019 |
.jpg) |
NEW DELHI: Drug major Cipla on Wednesday reported a marginal rise in consolidated net profit at ₹447.15 crore for the quarter ended June 30, 2019. The company had posted a net profit of ₹445.61 crore in the year-ago period, Cipla said in a filing to BSE. Read More |
|
|
Cipla arm InvaGen Pharma gets USFDA nod for neuropathic pain management drug
Posted on 22nd July 2019 |
.jpg) |
Drug major Cipla Monday said its subsidiary InvaGen Pharmaceuticals has received final approval from the US health regulator for Pregabalin Capsules, indicated for management of neuropathic pain associated with certain illnesses. InvaGen has received approval from the the United States Food and Drug Administration (USFDA) for the drug in the strengths of 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg, Cipla said in a regulatory filing. Read More |
|
|
Cipla Rating | Hold — Quarter results were ahead of expectations
Posted on 3rd June 2019 |
.jpg) |
Cipla reported Q4 results ahead of expectation led by gSensipar “at-risk” exclusivity launch. Ex of this, revenues were in line while margins were c100bps ahead of expectation. Management expects US business to grow in double digits in FY20 and base margins to improve though it did not quantify the level. Cipla trading at 20x FY21 PE, factors in the base business improvement. We retain Hold, noting the mixed execution over past 12m. Read More |
|
| Please click the link for more news |
|
|
|
.jpg)
